GLP-1 Receptor Agonist Use Linked to Lower Mortality in Seniors With Cancer, T2D

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on July 24, 2025.

via HealthDay

THURSDAY, July 24, 2025 -- For older patients with cancer and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with lower all-cause mortality than dipeptidyl peptidase-4 inhibitor (DPP4i) use, according to a study published online July 18 in JAMA Network Open.

Rotana M. Radwan, Ph.D., from the University of Florida in Gainesville, and colleagues examined whether GLP-1 RA use compared with sodium-glucose cotransporter-2 inhibitor (SGLT2i) and DPP4i use is associated with improved survival in patients with cancer and T2D in a retrospective cohort study using 2013 to 2020 Medicare data. Eligible patients were aged 66 years or older and had T2D and one of nine cancers (thyroid, pancreatic, bladder, colorectal, lung, kidney, breast, endometrial, or prostate). Propensity score matching was conducted to reduce confounding.

The GLP-1 RA versus SGLT2i cohort included 2,553 matched pairs, and the GLP-1 RA versus DPP4i cohort included 2,564 matched pairs. The researchers found no significant difference in mortality risk between GLP-1 RA and SGLT2i users. However, significantly lower mortality was seen in association with GLP-1 RA versus DPP4i use (hazard ratio, 0.60). The E-value was 1.21 and 2.73 for GLP-1 RA versus SGLT2i use and for GLP-1 RA versus DPP4i use, respectively. No significant differences were seen between GLP-1 RAs and SGLT2is in subgroup analyses; the survival benefit remained consistent across age, sex, non-Hispanic White race, and several cancer types (colorectal, lung, and breast) for GLP-1 RAs versus DPP4is.

"While causality cannot be inferred, our study adds novel evidence on the comparative effectiveness of GLP-1 RAs," the authors write. "The observed survival differences may reflect drug class-specific systemic effects."

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-07-25 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords